Hodges Capital Management’s NovoCure NVCR Stock Holding History

Hodges Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-20,000	Closed	-$4.44M	–	247
2021 Q2	$4.44M	Sell	20,000 -5,000	-20%	-$973K	0.5%	71
2021 Q1	$3.31M	Buy	25,000 +4,500	+22%	+$712K	0.46%	78
2020 Q4	$3.55M	Sell	20,500 -15,250	-43%	-$2.09M	0.56%	63
2020 Q3	$3.98M	Buy	+35,750	New	+$2.86M	0.77%	42
2019 Q1	–	Sell	-75,500	Closed	-$2.53M	–	242
2018 Q4	$2.53M	Sell	75,500 -66,250	-47%	-$2.42M	0.28%	82
2018 Q3	$7.43M	Sell	141,750 -88,250	-38%	-$3.51M	0.55%	52
2018 Q2	$7.2M	Sell	230,000 -55,500	-19%	-$1.54M	0.53%	61
2018 Q1	$6.22M	Buy	285,500 +12,000	+4%	+$258K	0.49%	58
2017 Q4	$5.53M	Buy	273,500 +63,000	+30%	+$1.21M	0.41%	72
2017 Q3	$4.18M	Buy	+210,500	New	+$4.14M	0.28%	85

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hodges Capital Management's NVCR Position: Q3 2021 in Review

Hodges Capital Management sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 20,000 shares — an estimated $4.44M sold.

Hodges Capital Management first reported a position in NVCR in Q3 2017 and held it in 10 quarters. The position peaked at $7.43M in Q3 2018. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

Hodges Capital Management reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
Hodges Capital Management sold 20,000 NovoCure shares in Q3 2021, an estimated $4.44M.
Hodges Capital Management first reported a position in NovoCure in Q3 2017 and held it in 10 quarters.
Hodges Capital Management's NovoCure position peaked at $7.43M in Q3 2018.
317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Hodges Capital Management's 13F filing for Q3 2021, filed 6 Oct 2021.